AI Article Synopsis
Article Abstract
Background: There is some evidence that Benign Prostatic Hyperplasia (BPH) may increase the risk of developing prostate cancer, so conducting research on effective BPH inhibitors is important.
Objective: This research studied the inhibitory effect of Iodized Serum Milk Protein (ISMP) on BPH in rats. ISMP is a concentrate of lactic protein containing 2.2% iodine.
Methods: Male Wistar rats, aged 18 months, were used. In the intact control group, sunflower oil was administered intragastrically by gavage. In 36 rats, BPH was induced by surgical castration, followed by subcutaneous injections of prolonged testosterone - omnadren, 25mg/kg every other day (7 administrations). One group of rats served as BPH-control. ISMP and finasteride (positive control), dissolved in sunflower oil, were administered to rats intragastrically daily at a dose of 200μg/kg and 5mg/kg, respectively, for 4 weeks starting immediately after castration.
Results: ISMP inhibited the development of BPH in rats, significantly reducing the mass of the prostate and its parts (except for the anterior lobes) by 1.1-1.3 times and the prostatic index (the ratio of prostate weight to the body weight) - by 1.3-1.4 times. Finasteride inhibited the development of BPH, and its activity was higher (by 1.1-1.3 times) than in ISMP. Histological analysis of the prostate showed fewer pronounced morphological hyperplasia signs in animals treated with ISMP or finasteride.
Conclusion: The iodine-containing preparation ISMP has the ability to inhibit the development of BPH in rats although its activity is somewhat lower than that of finasteride.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2174/1871520619666190705143927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
alleviates testosterone-induced benign prostatic hyperplasia by inhibiting 5α-reductase activity and androgen receptor signaling pathway.
Nutr Res Pract
December 2024
Department of Biochemistry, Dong-eui University College of Korean Medicine, Busan 47227, Korea.
Background/objectives: Recently, herbal medicines have gained attention for the treatment of benign prostatic hyperplasia (BPH), a common disease in elderly men. In this study, we aimed to determine the effect of ethanol extract of (EAR), which is traditionally used to treat various diseases, on BPH development using a testosterone-induced BPH model.
Materials/methods: Testosterone propionate (TP)-treated Sprague-Dawley rats were used to establish a BPH model .
Broad and diverse roles of sphingosine-1-phosphate/sphingosine-1-phosphate receptors in the prostate.
iScience
December 2024
Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
Article Synopsis
- Benign prostatic hyperplasia (BPH) is a common issue in older males, but how it develops is still not fully understood, prompting research into the role of sphingosine-1-phosphate (S1P) and its receptors (S1PRs) in the prostate.
- The study found that S1P and its receptors are highly expressed in the prostate, and S1PR1, S1PR2, and S1PR3 are involved in promoting cell growth, muscle contraction, and reducing inflammation via various cellular pathways.
- Treatment with S1P and specific receptor agonists led to prostate enlargement in rats, while antagonists of S1PR1 and S1PR3 reduced BPH symptoms
Fabrication and Optimization of a Silodosin In Situ-Forming PLGA Implants for the Treatment of Benign Prostatic Hyperplasia: In Vitro and In Vivo Study.
Pharmaceutics
October 2024
Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt.
Lower urinary tract symptoms (LUTSs) related to benign prostatic hyperplasia (BPH) are common in older men, and alpha-adrenoceptor blockers continue to be a key part of managing these symptoms. This study aimed to formulate injectable poly (lactic-co-glycolic acid) (PLGA) in situ-forming implants (ISFIs) loaded with silodosin (SLD) to address symptoms associated with BPH. This method, which ensures prolonged therapeutic effects of SLD, is intended to decrease dosing frequency and improve treatment outcomes, leading to better patient adherence.
View Article and Find Full Text PDFExtract Ameliorates Testosterone-Induced Benign Prostatic Hyperplasia by Regulating Androgen Levels, Cell Proliferation, and Apoptosis.
Pharmaceuticals (Basel)
November 2024
Department of Veterinary Pathology, College of Veterinary Medicine, Chungnam National University, Daejeon 34134, Republic of Korea.
Background/objectives: Benign prostatic hyperplasia (BPH) is a prevalent urological condition affecting elderly men. L. (PV), a perennial herbaceous plant native to Europe and Asia, has anti-inflammatory, antioxidant, and antimicrobial effects.
View Article and Find Full Text PDFSildenafil citrate induces prostatic hyperplasia in BPH model rats and aged rats.
Toxicol Appl Pharmacol
December 2024
NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Pharmacy School, Fudan University, Shanghai 200237, China; Department of Pharmacology & Toxicology, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai 200032, China. Electronic address:
Erectile dysfunction (ED), a prevalent disease among middle-aged and elderly males, significantly impacts both patient and partner quality of life. Phosphodiesterase type 5 inhibitor (PDE5i) represents an effective therapeutic method for ED. Given their widespread global utilization, concerns arise regarding potential reproduction-related problems arising from clinical use.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!